ClinicalTrials.gg
CompletedNCT04925661Updated May 15, 2025

HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

A Phase 1 interventional study of HEC53856 and Roxadustat in Chronic Kidney Diseases and Renal Anemia, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 8 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Enrollment
134th of 164
40 · median 182
Started
2021
with 19 others
Phase 1
20 of 245
10 open now
Registered
99th of 245
by date

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 134th largest by enrollment of the 164 interventional ones that give a count, is one of 20 that started in 2021, is one of 20 in phase 1, and was the 99th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety, tolerability , pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia.

Read the detailed description

This is a MultiCenter, Randomized, Blinded, Active Drug and Placebo-controlled, Dose-escalated Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia. Each part participants will be randomly administrated for HEC53856 or placebo or roxadustat.

The study consisted of three study periods as follows:

Screening period: up to 2 weeks; Treatment period: 8 weeks; Post-Treatment Follow-Up period: 4 weeks.

03

Conditions studied

  • Chronic Kidney Diseases
  • Renal Anemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who agree to participate in this clinical trial and sign an form;
  2. Age 18\~65 years old; Weight 40\~90Kg, including critical value;
  3. (eGFR) calculated by CKD-EPI formula 15mL/min/1.73 m\^2 \< or = eGFR \< 60 mL/min/1.73 m\^2 diagnosed chronic kidney disease patients who have not received dialysis;
  4. The values obtained during the last two screening periods at least 6 days apart must be > or = 8.0 g/dL and \<10 g/dL.

Exclusion criteria

Exclusion Criteria:

  1. Existence of diseases or conditions other than nephropathy that may cause anemia, including but not limited to 1) blood system diseases, such as thalassemia, aplastic anemia, hemolytic anemia, multiple myeloma, myelodysplastic syndrome, etc.; 2) may affect red blood cells The resulting diseases, such as systemic lupus erythematosus, rheumatoid arthritis, etc.; 3) Bleeding diseases, such as gastrointestinal bleeding, obstetrics and gynecology bleeding diseases, etc.; 4) Elective surgery expected during the study period;
  2. Drugs used to treat anemia within 8 weeks before the first administration, including but not limited to erythropoiesis stimulators (ESAs) and their derivatives, hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHI), androgens And anabolic hormone drugs, intravenous iron, Chinese patent medicine, Chinese herbal medicine, etc. (Can accept patients who have used a fixed dose of oral iron within 4 weeks before screening, and continue to take it during the screening period and the first 4 weeks after starting to take the test drug The fixed dose remains unchanged.);
  3. Those who have received blood transfusion within 3 months before the first administration;
  4. Folic acid \<6.8nmol/L (3ng/ml) and (or) VitB12\<74pmol/L (100ng/ml) during the screening period;
  5. chronic liver and gallbladder disease, or obvious abnormal liver function: >3× and/or AST>3×ULN, or total >1.5×ULN;
  6. Serum albumin \<3 g/dL;
  7. The mean systolic blood pressure > or = 160 mmHg and/or the diastolic blood pressure > or = 100 mmHg of the two blood pressure measurements at least one hour apart during the screening period;
  8. Suffering from uncontrollable or symptomatic secondary hyperparathyroidism, plasma iPTH > 500pg/ml;
  9. A history of acute or chronic pancreatitis, or acute or chronic pancreatitis at the time of screening, or blood amylase > or = 3×ULN;
  10. History of malignant tumors within 5 years (except for cured skin basal cell carcinoma and cervical carcinoma in situ), or current assessment of potential malignant tumors;
  11. Patients with acute coronary syndrome, stroke ( except for lacunar infarction )or thromboembolic diseases (such as deep vein thrombosis or pulmonary embolism) occurred in the 6 months before screening;
  12. New York Society of Cardiology, grade III or IV congestive heart failure, or severe arrhythmia, including but not limited to atrial fibrillation, III degree atrioventricular block, etc.;
  13. AIDS antibody, Treponema pallidum antibody, surface antigen or antibody positive for any of them;
  14. People with a history of severe allergic disease or drug allergy, or those who are allergic to experimental drugs or their ;
  15. Patients with clinically severe infections who are receiving systemic antibiotic treatment;
  16. Those who have started dialysis or plan to start dialysis treatment within 6 months;
  17. Anyone who has participated in or plans to participate in organ transplantation within 6 months;
  18. Patients with hemoglobinosis, polycystic kidney disease, or no kidney;
  19. Women during pregnancy or lactation, or fertile men and women who refuse to take effective measures voluntarily from the beginning of screening to 4 weeks after the administration of the last trial drug;
  20. Participated in other clinical trials within 3 months before screening (Definition of participation: accepted trial drug or instrument);
  21. The investigator believes that there are other factors that are not suitable for participating in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    HEC53856

    Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg

    Drug: HEC53856

  • Active comparator
    Roxadustat

    Drug: roxadustat TIW dosing There will be only one cohort: 70mg

    Drug: Roxadustat

  • Placebo comparator
    Placebo

    Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg

    Drug: Placebo

Interventions

  • Either dose of HEC53856 will be administered after fasting .

  • Roxadustat will be administered after fasting .

  • DrugPlacebo

    Either dose of placebo will be administered after fasting .

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    To assess the safety and tolerability of therapy by incidence of treatment-emergent adverse events after multiple doses of HEC53856 capsule

    Time frame: Through study completion, an average of 12 weeks.

Secondary outcomes

  1. AUC0-t

    Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  2. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  3. Tmax

    Time of the maximum observed plasma concentration

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  4. T½

    Apparent terminal elimination half-life

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  5. Vz/F

    Apparent volume of distribution

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  6. Changes in mean hemoglobin

    Changes in mean hemoglobin (Hb) relative to baseline during weeks 8 and 10.

    Time frame: week 10

  7. Hemoglobin response

    Percentage of subjects who met the hemoglobin response after dosing

    Time frame: week 10

  8. E-AUC0-t

    Area under the EPO concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  9. Emax

    Maximum observed EPO concentration

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  10. E-Tmax

    Time of the maximum observed EPO concentration

    Time frame: Day 1(Dosing) until Day 55 after single and multiple drug dosing.

  11. Serum lipid

    Changes in Serum lipid relative to baseline at weeks 8.

    Time frame: Up to Day 55

  12. Indicators of iron

    Changes in the Indicators of iron relative to baseline at weeks 8.

    Time frame: Up to Day 55

  13. High-sensitivity C-reactive protein

    Changes in the High-sensitivity C-reactive protein relative to baseline at weeks 8.

    Time frame: Up to Day 55

  14. Reticulocytes

    Changes in the mean Reticulocytes relative to baseline after doses.

    Time frame: Up to Day 85

  15. VEGF

    Changes in the VEGF relative to baseline after doses.

    Time frame: Up to Day 55

07

Study locations

8 sites
  • The sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
  • Zhejiang Provincal People's Hospital
    Hangzhou, China
  • The People's Hospital of Guangxi Zhuang Autonmous Region
    Nanning, China
  • Huashan Hospital
    Shanghai, China
  • Ruijin Hospital
    Shanghai, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2023, 21 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 21 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2021
First posted
Jun 14, 2021
StartActual
Nov 4, 2021
Primary completionActual
Aug 29, 2023
CompletionActual
Aug 29, 2023
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04925661
Collaborators
Nicoya Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Nov 4, 2021
Primary completion
Aug 29, 2023
Completion
Aug 29, 2023
Last update
May 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HEC53856

Start the discussion